AstraZeneca (NYSE:AZN) is one of the globe's biggest drug companies. The company generates more than $20 billion in annual sales, and given its dividend yield is nearly 4%, its shares are often included in dividend investor's portfolios.

Although AstraZeneca has recently jumped because of M&A interest from Pfizer (NYSE:PFE), investors are right to wonder whether patent expiration on top selling drugs and falling margin could threaten AstraZeneca's dividend if it remains an independent company.

In the following slideshow you'll learn whether I think AstraZeneca's dividend is safe and see how AstraZeneca's dividend matches up to Pfizer and former diabetes partner Bristol-Myers (NYSE:BMY).


Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.